CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Survey administrationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug377 Blood sample Wiki 0.33

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)

ONCOVID is a prospective cohort study investigating oncology-patient-reported anxiety, mood, and quality of life during the COVID-19 pandemic. Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (COVID-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, and WHO Quality of Life-BREF). Data collection occurs at baseline and follow-up surveys are performed after 6, 12, and 24 weeks.

NCT04340219 Cancer Other: Survey administration
MeSH:Anxiety Disorders

Primary Outcomes

Measure: Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs ≥ 29).

Time: Week 0

Measure: Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs ≥ 5).

Time: Week 0

Measure: Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs ≥ 4).

Time: Week 0

Measure: Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs ≥ 8).

Time: Week 0

Secondary Outcomes

Measure: Distress measured at baseline by the CPDI; in terms of continuous values.

Time: Week 0

Measure: Depression at baseline measured by the DASS-21—Depression; in terms of continuous values.

Time: Week 0

Measure: Anxiety at baseline measured by the DASS-21—Anxiety; in terms of continuous values.

Time: Week 0

Measure: Stress at baseline measured by the DASS-21—Stress; in terms of continuous values.

Time: Week 0

Measure: Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF—Physical health); in terms of continuous values.

Time: Week 0

Measure: Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Psychological health); in terms of continuous values.

Time: Week 0

Measure: Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Social relationships); in terms of continuous values.

Time: Week 0

Measure: Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Environment); in terms of continuous values.

Time: Week 0

Measure: Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire—in terms of continuous values.

Time: Week 0

Measure: Change from baseline in distress measured by CDPI; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in depression measured by the DASS-21—Depression; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in anxiety measured by the DASS-21—Anxiety; in terms of continues values.

Time: 24 weeks

Measure: Change from baseline in stress measured by the DASS-21—Stress; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Physical health; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Psychological health; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Social relationship; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Environment; in terms of continuous values.

Time: 24 weeks

Measure: Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.

Time: 24 weeks

Measure: The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics

Time: Week 0-6-12-24

No related HPO nodes (Using clinical trials)